Welhart 150mg Capsule contains Mexiletine, a class 1B antiarrhythmic agent used primarily for the management of ventricular arrhythmias. Mexiletine acts by blocking sodium channels in the cardiac muscle, thereby stabilizing the myocardial cell membrane and reducing abnormal electrical activity that can lead to irregular heartbeats. It is indicated for the treatment of life-threatening ventricular arrhythmias, including ventricular tachycardia and premature ventricular contractions, particularly in patients who are refractory to other antiarrhythmic therapies or when other treatments are contraindicated. Welhart 150mg is administered orally, with dosage individualized based on the patient’s clinical response and tolerance. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and dyspepsia, as well as neurological symptoms like dizziness, tremors, or ataxia. Caution is advised in patients with hepatic or renal impairment, and it should be used under strict medical supervision due to the potential for proarrhythmic effects. Mexiletine may interact with other antiarrhythmic drugs, CNS depressants, and certain antibiotics, necessitating careful monitoring. Regular cardiac evaluation and periodic blood tests are recommended during therapy to ensure efficacy and safety. Welhart 150mg Capsule should be prescribed and used according to professional medical guidance.